Shots:

• Marinus to receive ~$30M up front & is eligible to receive ~$115M in R&D reimbursement milestone on achievement of clinical & commercialization milestones along with royalties. The transaction is expected to be completed in Q1’22
• Orion gets exclusive rights to commercialize ganaxolone as PO & IV formulations in EU- UK & Switzerland for CDD- TSC & RSE. The therapy is expected to be launch in mid-2022
• Marinus will be responsible for clinical development of ganaxolone along with approvals & submissions & is expected to file an MAA for the therapy to treat CDD in Q3’21. Orion will lead all pricing and reimbursement approvals along with the commercialization of ganaxolone in the EU

 to   | Ref: Businesswire | Image: Businesswire